This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brion, J. P. Articles by Couck, A. M. Search for Related Content PubMed PubMed Citation Articles by Brion, J. P. Articles by Couck, A. M.

American Journal of Pathology, Vol 147, 1465-1476, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5

JP Brion and AM Couck
Laboratory of Pathology and Electron Microscopy, Free University of Brussels, Belgium.

The immunoreactivity of cortical and brainstem-type Lewy bodies has been investigates with antibodies to the cyclin-dependent kinase 5 (cdk5), to the extracellular regulated kinase 1 (ERK-1), and to the cdc2p34 kinase and with antibodies specific for phosphorylation epitopes typical of paired helical filament-tau (PHF-tau). Both cortical and brainstem-type Lewy bodies in diffuse Lewy body disease and brainstem-type Lewy bodies in Parkinson's disease were found to be immunoreactive for cdk5 but not for cdc2p34 or ERK-1 or with the PHF- tau antibodies. Double immunolabeling showed that cdk5-positive Lewy bodies were also ubiquitin immunoreactive and that cdk5 antibodies labeled as many Lewy bodies as ubiquitin antibodies in adequately fixed tissue. The cdk5 immunoreactivity of Lewy bodies was abolished by preabsorption of the antibody with a cdk5 peptide. The antibodies to cdk5 labeled a single 33-kd species on Western blots of human brain homogenates, with a similar intensity in control, diffuse Lewy body disease, and Alzheimer's disease, and this cdk5 species was found mainly in the particulate fraction of brain homogenates. This observation suggests that cdk5 might be a protein kinase involved in the phosphorylation of a molecular component of Lewy bodies, for example, neurofilament proteins known to be present in these inclusions.

This article has been cited by other articles:

				R. Endo, T. Saito, A. Asada, H. Kawahara, T. Ohshima, and S.-i. Hisanaga Commitment of 1-Methyl-4-phenylpyrinidinium Ion-induced Neuronal Cell Death by Proteasome-mediated Degradation of p35 Cyclin-dependent Kinase 5 Activator J. Biol. Chem., September 18, 2009; 284(38): 26029 - 26039. [Abstract] [Full Text] [PDF]

				E. Rubio de la Torre, B. Luzon-Toro, I. Forte-Lago, A. Minguez-Castellanos, I. Ferrer, and S. Hilfiker Combined kinase inhibition modulates parkin inactivation Hum. Mol. Genet., March 1, 2009; 18(5): 809 - 823. [Abstract] [Full Text] [PDF]

				E. Avraham, R. Rott, E. Liani, R. Szargel, and S. Engelender Phosphorylation of Parkin by the Cyclin-dependent Kinase 5 at the Linker Region Modulates Its Ubiquitin-Ligase Activity and Aggregation J. Biol. Chem., April 27, 2007; 282(17): 12842 - 12850. [Abstract] [Full Text] [PDF]

				S. Gandhi, M. M. K. Muqit, L. Stanyer, D. G. Healy, P. M. Abou-Sleiman, I. Hargreaves, S. Heales, M. Ganguly, L. Parsons, A. J. Lees, et al. PINK1 protein in normal human brain and Parkinson's disease Brain, July 1, 2006; 129(7): 1720 - 1731. [Abstract] [Full Text] [PDF]

				X. Tang, X. Wang, X. Gong, M. Tong, D. Park, Z. Xia, and Z. Mao Cyclin-Dependent Kinase 5 Mediates Neurotoxin-Induced Degradation of the Transcription Factor Myocyte Enhancer Factor 2 J. Neurosci., May 11, 2005; 25(19): 4823 - 4834. [Abstract] [Full Text] [PDF]

				L. Y. Moy and L.-H. Tsai Cyclin-dependent Kinase 5 Phosphorylates Serine 31 of Tyrosine Hydroxylase and Regulates Its Stability J. Biol. Chem., December 24, 2004; 279(52): 54487 - 54493. [Abstract] [Full Text] [PDF]

				Y. Zhou, G. Gu, D. R. Goodlett, T. Zhang, C. Pan, T. J. Montine, K. S. Montine, R. H. Aebersold, and J. Zhang Analysis of {alpha}-Synuclein-associated Proteins by Quantitative Proteomics J. Biol. Chem., September 10, 2004; 279(37): 39155 - 39164. [Abstract] [Full Text] [PDF]

				J. L. Hallows, K. Chen, R. A. DePinho, and I. Vincent Decreased Cyclin-Dependent Kinase 5 (cdk5) Activity Is Accompanied by Redistribution of cdk5 and Cytoskeletal Proteins and Increased Cytoskeletal Protein Phosphorylation in p35 Null Mice J. Neurosci., November 19, 2003; 23(33): 10633 - 10644. [Abstract] [Full Text] [PDF]

				P. D. Smith, S. J. Crocker, V. Jackson-Lewis, K. L. Jordan-Sciutto, S. Hayley, M. P. Mount, M. J. O'Hare, S. Callaghan, R. S. Slack, S. Przedborski, et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease PNAS, November 11, 2003; 100(23): 13650 - 13655. [Abstract] [Full Text] [PDF]

				C. M. Sahlgren, A. Mikhailov, S. Vaittinen, H.-M. Pallari, H. Kalimo, H. C. Pant, and J. E. Eriksson Cdk5 Regulates the Organization of Nestin and Its Association with p35 Mol. Cell. Biol., July 15, 2003; 23(14): 5090 - 5106. [Abstract] [Full Text] [PDF]

				A. Catania, S. Urban, E. Yan, C. Hao, G. Barron, and J. Allalunis-Turner Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells Neuro-oncol, April 1, 2001; 3(2): 89 - 98. [Abstract] [PDF]

				S. Nakano, I. Akiguchi, S. Nakamura, H. Satoi, S. Kawashima, and J. Kimura Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis Neurology, November 1, 1999; 53(8): 1671 - 1671. [Abstract] [Full Text] [PDF]